Type 1 diabetes (T1D) is a T cell mediated autoimmune disease, where insulin-producing pancreatic beta-ceils are destroyed by autoaggressive CD4 and CD8 lymphocytes. Importantly, autoreactive T cells are found in the peripheral blood of most individuals, but are usually not activated. Thus, true tolerance in the sense of complete absence of autoreactive lymphocytes by thymic negative selection or peripheral deletion appears to be uncommon for certain autoantigens. Several issues are still unclear and will be addressed by this proposal. One can assume that any autoaggressive response will initially target only a few autoantigens before it engulfs and spreads to other antigens released during the inflammatory process. It will be of high therapeutic and pathogenetic interest, whether initiating lymphocytes directed to the primary autoantigens must be present as """"""""drivers"""""""" throughout the pre-diabetic phase. Conversely, we do not know whether antigenic spreading, although it occurs in T1D, is a pathogenetically vital process. One would like to understand if all or how many of the antigenic specificities, (including 'new entries') present in an islet infiltrate or pancreatic draining lymph node contribute to pathogenesis. Our first question is whether an initiating autoantigen needs to be expressed throughout the autoimmune process in order to maintain activated, autoaggressive driver T cells (Aim 1). Second, we would like to ask, how the addition of a non-tolerant autoantigen into an already established autoimmune process will influence (accelerate?) the disease course, since a sufficient number of 'driver clones' seeing other autoantigens has already been established (Aim 2). These studies will use a tetracycline-dependent promoter system to 'subtract' the initiating autoantigen from the autoimmune process at different times using the RIP-LCMV model for type I diabetes (Aim 1) and to express a non-tolerant autoantigen at different phases during spontaneous autoimmunity in the NOD mouse and in this way quantitatively address the pathogenetic importance of antigenic spreading during different phases of the disease process (Aim 2). We believe that these two goals will greatly improve our understanding of how autoantigens are driving an autoaggressive process and during which phases of the diabetogenic response the initiating antigen(s) are important.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI044451-07
Application #
7002721
Study Section
Immunological Sciences Study Section (IMS)
Program Officer
Ridge, John P
Project Start
1998-09-30
Project End
2007-12-31
Budget Start
2006-01-01
Budget End
2006-12-31
Support Year
7
Fiscal Year
2006
Total Cost
$278,010
Indirect Cost
Name
La Jolla Institute
Department
Type
DUNS #
603880287
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Bresson, Damien; Fousteri, Georgia; Manenkova, Yulia et al. (2011) Antigen-specific prevention of type 1 diabetes in NOD mice is ameliorated by OX40 agonist treatment. J Autoimmun 37:342-51
Van Belle, Tom L; Juntti, Therese; Liao, Jeanette et al. (2010) Pre-existing autoimmunity determines type 1 diabetes outcome after Flt3-ligand treatment. J Autoimmun 34:445-52
Filippi, Christophe M; Juedes, Amy E; Oldham, Janine E et al. (2008) Transforming growth factor-beta suppresses the activation of CD8+ T-cells when naive but promotes their survival and function once antigen experienced: a two-faced impact on autoimmunity. Diabetes 57:2684-92
Bresson, D; von Herrath, M (2007) Moving towards efficient therapies in type 1 diabetes: to combine or not to combine? Autoimmun Rev 6:315-22
Martinic, Marianne M; Juedes, Amy E; Bresson, Damien et al. (2007) Minimal impact of a de novo-expressed beta-cell autoantigen on spontaneous diabetes development in NOD mice. Diabetes 56:1059-68
Burrer, Renaud; Buchmeier, Michael J; Wolfe, Tom et al. (2007) Exacerbated pathology of viral encephalitis in mice with central nervous system-specific autoantibodies. Am J Pathol 170:557-66
Barral, Ana Maria; Thomas, Helen E; Ling, Eleanor M et al. (2006) SOCS-1 protects from virally-induced CD8 T cell mediated type 1 diabetes. J Autoimmun 27:166-73
Burrer, Renaud; von Herrath, Matthias G; Wolfe, Tom et al. (2006) Autoantibodies exacerbate the severity of MHV-induced encephalitis. Adv Exp Med Biol 581:399-402
Christen, Urs; von Herrath, Matthias G (2005) Infections and autoimmunity--good or bad? J Immunol 174:7481-6
Rhode, Antje; Pauza, Mary E; Barral, Ana Maria et al. (2005) Islet-specific expression of CXCL10 causes spontaneous islet infiltration and accelerates diabetes development. J Immunol 175:3516-24

Showing the most recent 10 out of 33 publications